Original Publication Date: 1 August, 2015
Publication / Source: Future Oncology
Authors: Lucia Del Mastro, Marina Cazzaniga, Paolo Solidoro et al
Everolimus – an inhibitor of the mTOR pathway – has an established role in the treatment of advanced renal cell cancer (RCC), neuroendocrine tumors of pancreatic origin (pNET) and renal angiomyolipoma and tuberous sclerosis complex (TSC) . Moreover, everolimus, combined with the aromatase inhibitor exemestane, has been approved for the treatment of postmenopausal patients with advanced breast cancer positive for the hormone receptors (HR+) and negative for the HER2– recurring or progressing after treatment with nonsteroidal aromatase inhibitors . Everolimus is administered orally, at a dose of 10 mg/day continuously. At this dosage, no evidence of cumulative toxicity has been reported in clinical trials over a period of 20–52 weeks .